Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengyong Wu

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Biochemical and Biophysical Research Communications|February 23, 2020
Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug designTao Wang, Chengyong Wu, Chengdi Wang, et al.
Journal of Hazardous Materials|December 14, 2020
Label-free DNAzyme assays for dually amplified and one-pot detection of lead pollutionYong Zhang, Chengyong Wu, Hongxin Liu, et al.
Biochemical and Biophysical Research Communications|February 27, 2019
Molecular mechanism of crolibulin in complex with tubulin provides a rationale for drug designZhixiong Zhang, Chengdi Wang, Lingling Ma, et al.
Signal Transduction and Targeted Therapy|February 20, 2025
A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategyHuan Xiao, Aoxue Wang, Wen Shuai, et al.
Analytical Chemistry|June 24, 2024
Steric Hindrance-Mediated Enzymatic Reaction Enable Homogeneous Dual Fluorescence Indicators Aptasensing of Hepatocellular Carcinoma CTCsPengjun Jiang, Zixuan Zhan, Yufu Peng, et al.
Journal of Medicinal Chemistry|February 7, 2024
Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR<sup>L858R/T790M</sup>/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung CancersAoxue Wang, Wen Shuai, Chengyong Wu, et al.
Journal of Medicinal Chemistry|April 12, 2023
Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung CancerJunping Pei, Guan Wang, Aoxue Wang, et al.
International Immunopharmacology|March 13, 2026
NLRP3 and CCR1 drive offspring asthma susceptibility following maternal RSV infectionHuisha Xu, Yingying Du, Zaopin Zeng, et al.
Journal of Medicinal Chemistry|April 19, 2019
Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor BromodomainLuyi Huang, Hui Li, Linli Li, et al.
Nucleic Acids Research|February 23, 2021
Mechanisms of spacer acquisition by sequential assembly of the adaptation module in SynechocystisChengyong Wu, Dongmei Tang, Jie Cheng, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Biochemical and Biophysical Research Communications|February 23, 2020
Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug designTao Wang, Chengyong Wu, Chengdi Wang, et al.
Journal of Hazardous Materials|December 14, 2020
Label-free DNAzyme assays for dually amplified and one-pot detection of lead pollutionYong Zhang, Chengyong Wu, Hongxin Liu, et al.
Biochemical and Biophysical Research Communications|February 27, 2019
Molecular mechanism of crolibulin in complex with tubulin provides a rationale for drug designZhixiong Zhang, Chengdi Wang, Lingling Ma, et al.
Signal Transduction and Targeted Therapy|February 20, 2025
A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategyHuan Xiao, Aoxue Wang, Wen Shuai, et al.
Analytical Chemistry|June 24, 2024
Steric Hindrance-Mediated Enzymatic Reaction Enable Homogeneous Dual Fluorescence Indicators Aptasensing of Hepatocellular Carcinoma CTCsPengjun Jiang, Zixuan Zhan, Yufu Peng, et al.
Journal of Medicinal Chemistry|February 7, 2024
Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR<sup>L858R/T790M</sup>/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung CancersAoxue Wang, Wen Shuai, Chengyong Wu, et al.
Journal of Medicinal Chemistry|April 12, 2023
Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung CancerJunping Pei, Guan Wang, Aoxue Wang, et al.
International Immunopharmacology|March 13, 2026
NLRP3 and CCR1 drive offspring asthma susceptibility following maternal RSV infectionHuisha Xu, Yingying Du, Zaopin Zeng, et al.
Journal of Medicinal Chemistry|April 19, 2019
Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor BromodomainLuyi Huang, Hui Li, Linli Li, et al.
Nucleic Acids Research|February 23, 2021
Mechanisms of spacer acquisition by sequential assembly of the adaptation module in SynechocystisChengyong Wu, Dongmei Tang, Jie Cheng, et al.
Pageof 6